Atossa Therapeutics Inc (ATOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2016 | 09-2016 | 06-2016 | 03-2016 | 12-2015 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -6,369 | -3,845 | -4,050 | -2,328 | -15,760 |
| Depreciation Amortization | 304 | 227 | 153 | 76 | 273 |
| Accounts payable and accrued liabilities | -560 | -617 | -532 | -385 | 301 |
| Other Working Capital | -1,068 | -1,214 | -1,313 | -1,099 | 326 |
| Other Operating Activity | 2,319 | 1,430 | 1,088 | 741 | 907 |
| Operating Cash Flow | $-5,375 | $-4,019 | $-4,654 | $-2,995 | $-13,953 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -9 | -5 | -5 | -5 | -131 |
| Other Investing Activity | 0 | 0 | 0 | 0 | -158 |
| Investing Cash Flow | $-9 | $-5 | $-5 | $-5 | $-288 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 4,696 | 4,696 | 2,134 | 2,167 | 9,457 |
| Financing Cash Flow | $4,696 | $4,696 | $2,134 | $2,167 | $9,457 |
| Beginning Cash Position | 3,716 | 3,716 | 3,716 | 3,716 | 8,501 |
| End Cash Position | 3,028 | 4,388 | 1,191 | 2,883 | 3,716 |
| Net Cash Flow | $-688 | $672 | $-2,525 | $-833 | $-4,785 |
| Free Cash Flow | |||||
| Operating Cash Flow | -5,375 | -4,019 | -4,654 | -2,995 | -13,953 |
| Capital Expenditure | -9 | -5 | -5 | -5 | -131 |
| Free Cash Flow | -5,384 | -4,024 | -4,659 | -3,000 | -14,084 |